HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

A novel Tn antigen epitope‑recognizing antibody for MUC1 predicts clinical outcome in patients with primary lung adenocarcinoma

This item is licensed under:Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International

Files in This Item:
Oncol Lett 21(3) 202.pdf2.81 MBPDFView/Open
Please use this identifier to cite or link to this item:

Title: A novel Tn antigen epitope‑recognizing antibody for MUC1 predicts clinical outcome in patients with primary lung adenocarcinoma
Authors: Kato, Tatsuya Browse this author
Ujiie, Hideki Browse this author
Hatanaka, Kanako Browse this author
Nange, Ayae Browse this author
Okumura, Asami Browse this author
Tsubame, Kaho Browse this author
Naruchi, Kentato Browse this author
Sato, Masaharu Browse this author
Kaga, Kichizo Browse this author
Matsuno, Yoshihiro Browse this author
Wakasa, Satoru Browse this author
Hatanaka, Yutaka Browse this author
Keywords: mucin 1
Tn antigen
epitope‑defined antibody
epithelial‑mesenchymal transition
prognostic factor
lung cancer
Issue Date: 1-Mar-2021
Publisher: Spandidos Publications
Journal Title: Oncology Letters
Volume: 21
Issue: 3
Start Page: 202
Publisher DOI: 10.3892/ol.2021.12463
Abstract: Mucin 1 (MUC1) expression is upregulated in multiple types of cancer, including lung cancer. However, the conventional anti‑MUC1 antibody is not useful for the differentiation of malignant lung tumors and benign lesions due to its limited specificity. Our previous study screened a novel epitope‑defined antibody against cancer‑associated sugar chain structures that specifically recognizes the MUC1 Tn antigen (MUC1‑Tn ED Ab). In the present study, its potential utility as a diagnostic marker and therapeutic tool for lung adenocarcinoma (ADC) was examined. Immunohistochemical analysis of a lung ADC tissue microarray was performed using the MUC1‑Tn ED Ab (clone SN‑102), and the results were compared with those of another clone and commercially available MUC1 antibodies. The association between positive immunoreactivity of SN‑102 and clinicopathologic factors was analyzed. Furthermore, the association between MUC1‑Tn expression and epithelial‑mesenchymal transition markers and radiological characteristics was analyzed. Moderate or high MUC1‑Tn expression (MUC1‑Tn‑H) was observed in 138 (78.9%) of the 175 lung ADC cases. MUC1‑Tn‑H was associated with male sex, cigarette smoking, tumor extension, pleural invasion, and higher preoperative serum carcinoembryonic antigen and cytokeratin 19 fragment levels. Tumors with MUC1‑Tn‑H had higher consolidation/tumor ratios according to computed tomography and greater uptakes of 18F‑fluorodeoxyglucose. A total of 46 (26.9%) of the tumors had mesenchymal features, and MUC1‑Tn positivity was higher in the mesenchymal group than in the epithelial and intermediate groups (P<0.01 and P<0.01, respectively). Patients with tumors exhibiting MUC1‑Tn‑H had significantly shorter 5‑year overall and disease‑free survival times (P=0.011 and P<0.001, respectively). Additionally, MUC1‑Tn‑H was identified as an independent prognostic factor in multivariate analysis (P=0.024). MUC1‑Tn is specific for lung cancer cells and can improve diagnostic capabilities. Additionally, it may be a potential therapeutic target in lung ADC.
Type: article
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 氏家 秀樹

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University